Genentech begins phase 2 clinical trial of ranibizumab port delivery system for wet AMD

Genentech has initiated a phase 2 clinical trial of the ranibizumab port delivery system implant in patients with wet age-related macular degeneration, according to a company announcement.The Long Acting Delivery of Ranibizumab (LADDER) study will evaluate the safety and efficacy of the ranibizumab port delivery system (RPDS) implant for the sustained delivery of Lucentis for the treatment of wet AMD.